Janux Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Janux Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||
| current assets: | |||||||||||||||||
| cash and cash equivalents | 52,446,000 | 73,743,000 | 430,605,000 | 26,754,000 | 14,662,000 | 212,803,000 | 19,205,000 | 17,152,000 | 33,703,000 | 30,355,000 | 51,426,000 | 64,752,000 | 58,403,000 | 55,129,000 | 35,582,000 | 39,389,000 | 251,625,000 |
| short-term investments | 943,565,000 | 940,403,000 | 594,568,000 | 631,277,000 | 631,631,000 | 438,960,000 | 324,823,000 | 332,560,000 | 269,586,000 | 286,520,000 | 275,590,000 | 274,008,000 | 295,893,000 | 306,071,000 | 339,383,000 | 348,118,000 | 142,570,000 |
| prepaid expenses and other current assets | 9,542,000 | 9,193,000 | 8,493,000 | 8,290,000 | 8,146,000 | 6,384,000 | 5,213,000 | 5,483,000 | 6,013,000 | 3,774,000 | 5,423,000 | 5,070,000 | 3,769,000 | 3,454,000 | 2,054,000 | 2,081,000 | 2,038,000 |
| total current assets | 1,005,553,000 | 1,023,339,000 | 1,033,666,000 | 666,321,000 | 661,939,000 | 658,666,000 | 349,241,000 | 355,195,000 | 309,302,000 | 321,399,000 | 332,439,000 | 344,330,000 | 358,065,000 | 364,654,000 | 377,019,000 | 389,588,000 | 396,608,000 |
| restricted cash | 816,000 | 816,000 | 816,000 | 816,000 | 816,000 | 816,000 | 816,000 | 816,000 | 816,000 | 816,000 | 816,000 | 816,000 | 816,000 | 816,000 | 816,000 | ||
| property and equipment | 4,688,000 | 4,947,000 | 4,864,000 | 5,373,000 | 5,940,000 | 6,517,000 | 7,003,000 | 7,317,000 | 7,378,000 | 7,203,000 | 7,086,000 | 6,514,000 | 3,517,000 | 2,660,000 | 1,412,000 | 1,118,000 | 215,000 |
| operating lease right-of-use assets | 18,462,000 | 18,878,000 | 19,286,000 | 19,686,000 | 20,077,000 | 20,461,000 | 20,838,000 | 21,208,000 | 21,571,000 | 21,927,000 | 22,279,000 | 22,663,000 | 22,760,000 | 130,000 | 185,000 | 238,000 | |
| other long-term assets | 2,693,000 | 2,792,000 | 2,884,000 | 2,823,000 | 2,640,000 | 2,524,000 | 2,509,000 | 2,314,000 | 2,433,000 | 1,611,000 | 1,390,000 | 1,433,000 | 207,000 | 337,000 | 392,000 | 140,000 | |
| total assets | 1,032,212,000 | 1,050,772,000 | 1,061,516,000 | 695,019,000 | 691,412,000 | 688,984,000 | 380,407,000 | 386,850,000 | 341,500,000 | 352,956,000 | 364,010,000 | 375,756,000 | 385,365,000 | 368,597,000 | 379,824,000 | 391,084,000 | 396,823,000 |
| liabilities and stockholders’ equity | |||||||||||||||||
| current liabilities: | |||||||||||||||||
| accounts payable | 3,477,000 | 2,351,000 | 4,026,000 | 2,462,000 | 1,253,000 | 2,254,000 | 2,424,000 | 2,505,000 | 1,910,000 | 2,051,000 | 2,159,000 | 2,866,000 | 3,000,000 | 1,939,000 | 2,458,000 | 3,613,000 | 354,000 |
| accrued expenses | 16,029,000 | 13,340,000 | 11,684,000 | 13,022,000 | 8,568,000 | 5,810,000 | 7,387,000 | ||||||||||
| current portion of operating lease liabilities | 1,873,000 | 1,811,000 | 1,749,000 | 1,689,000 | 1,630,000 | 1,573,000 | 1,517,000 | 1,462,000 | 1,408,000 | 1,356,000 | 763,000 | 88,000 | 153,000 | 194,000 | 212,000 | ||
| total current liabilities | 21,379,000 | 17,502,000 | 17,459,000 | 17,173,000 | 11,545,000 | 10,609,000 | 13,033,000 | 14,471,000 | 17,904,000 | 16,114,000 | 16,507,000 | 16,335,000 | 12,994,000 | 12,515,000 | 12,797,000 | 12,471,000 | 9,205,000 |
| operating lease liabilities, net of current portion | 20,317,000 | 20,801,000 | 21,276,000 | 21,742,000 | 22,190,000 | 22,612,000 | 23,025,000 | 23,431,000 | 23,820,000 | 24,184,000 | 24,542,000 | 24,092,000 | 23,268,000 | 23,000 | |||
| total liabilities | 41,696,000 | 38,303,000 | 38,735,000 | 38,915,000 | 33,735,000 | 33,221,000 | 36,058,000 | 37,902,000 | 42,031,000 | 41,692,000 | 43,270,000 | 44,243,000 | 41,551,000 | 12,515,000 | 13,497,000 | 14,334,000 | 12,028,000 |
| commitments and contingencies | |||||||||||||||||
| stockholders’ equity: | |||||||||||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at june 30, 2025 and december 31, 2024; no shares issued and outstanding at june 30, 2025 and december 31, 2024 | |||||||||||||||||
| common stock | 59,000 | 59,000 | 59,000 | 52,000 | 52,000 | 51,000 | 46,000 | 46,000 | 42,000 | 42,000 | 42,000 | 42,000 | 42,000 | 41,000 | 41,000 | 41,000 | 41,000 |
| additional paid-in capital | 1,281,833,000 | 1,269,919,000 | 1,258,316,000 | 865,762,000 | 848,723,000 | 839,759,000 | 512,401,000 | 507,082,000 | 445,924,000 | 439,890,000 | 432,703,000 | 428,153,000 | 423,388,000 | 418,429,000 | 413,967,000 | 410,680,000 | 407,966,000 |
| accumulated other comprehensive income | 3,747,000 | 3,756,000 | 2,163,000 | 7,831,000 | -1,616,000 | -524,000 | 665,000 | -270,000 | 24,000 | 17,000 | |||||||
| accumulated deficit | -295,123,000 | -261,265,000 | -237,757,000 | -217,541,000 | -189,482,000 | -183,523,000 | -168,763,000 | -157,005,000 | -145,437,000 | -127,929,000 | -110,470,000 | -94,405,000 | -77,709,000 | -60,821,000 | -47,411,000 | -33,995,000 | -23,229,000 |
| total stockholders’ equity | 990,516,000 | 1,012,469,000 | 1,022,781,000 | 656,104,000 | 657,677,000 | 655,763,000 | 344,349,000 | 348,948,000 | 299,469,000 | 311,264,000 | 320,740,000 | 331,513,000 | 343,814,000 | 356,082,000 | 366,327,000 | 376,750,000 | 384,795,000 |
| total liabilities and stockholders’ equity | 1,032,212,000 | 1,050,772,000 | 1,061,516,000 | 695,019,000 | 691,412,000 | 688,984,000 | 380,407,000 | 386,850,000 | 341,500,000 | 352,956,000 | 364,010,000 | 375,756,000 | 385,365,000 | 368,597,000 | |||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at march 31, 2025 and december 31, 2024; no shares issued and outstanding at march 31, 2025 and december 31, 2024 | |||||||||||||||||
| current portion of deferred revenue | 94,000 | 972,000 | 1,705,000 | 3,648,000 | 5,340,000 | 4,935,000 | 5,406,000 | 5,906,000 | 5,371,000 | 4,649,000 | 5,163,000 | 5,264,000 | 5,065,000 | ||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at december 31, 2024 and 2023, respectively; no shares issued and outstanding at december 31, 2024 and 2023 | |||||||||||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at september 30, 2024 and december 31, 2023, respectively; no shares issued and outstanding at september 30, 2024 and december 31, 2023 | |||||||||||||||||
| accounts receivable | 7,500,000 | 519,000 | 750,000 | 500,000 | 375,000 | ||||||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at june 30, 2024 and december 31, 2023, respectively; no shares issued and outstanding at june 30, 2024 and december 31, 2023 | |||||||||||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at march 31, 2024 and december 31, 2023, respectively; no shares issued and outstanding at march 31, 2024 and december 31, 2023 | |||||||||||||||||
| deferred revenue, net of current portion | 307,000 | 1,394,000 | 2,221,000 | 3,816,000 | 5,289,000 | 700,000 | 1,840,000 | 2,823,000 | |||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at december 31, 2023 and 2022, respectively; no shares issued and outstanding at december 31, 2023 and 2022 | |||||||||||||||||
| accrued liabilities | 6,831,000 | 9,216,000 | 7,737,000 | 8,010,000 | 7,240,000 | 4,043,000 | 5,074,000 | 3,779,000 | 2,030,000 | 2,286,000 | |||||||
| unvested stock liabilities | 25,000 | 30,000 | 35,000 | 169,000 | 323,000 | 492,000 | 700,000 | 1,203,000 | 1,352,000 | ||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at september 30, 2023 and december 31, 2022, respectively; no shares issued and outstanding at september 30, 2023 and december 31, 2022 | |||||||||||||||||
| accumulated other comprehensive loss | -1,175,000 | -1,060,000 | -739,000 | -1,535,000 | -2,277,000 | -1,907,000 | -1,567,000 | ||||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at june 30, 2023 and december 31, 2022, respectively; no shares issued and outstanding at june 30, 2023 and december 31, 2022 | |||||||||||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at march 31, 2023 and december 31, 2022, respectively; no shares issued and outstanding at march 31, 2023 and december 31, 2022 | |||||||||||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at december 31, 2022 and 2021, respectively; no shares issued and outstanding at december 31, 2022 and 2021 | |||||||||||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at september 30, 2022 and december 31, 2021, respectively; no shares issued and outstanding at september 30, 2022 and december 31, 2021 | |||||||||||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at june 30, 2022 and december 31, 2021, respectively; no shares issued and outstanding at june 30, 2022 and december 31, 2021 | |||||||||||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 at march 31, 2022 and december 31, 2021, respectively; no shares issued and outstanding at march 31, 2022 and december 31, 2021 | |||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ equity | |||||||||||||||||
| convertible preferred stock, 0.001 par value; authorized shares – 0 and 6,838,829 at december 31, 2021 and 2020, respectively; issued and outstanding shares – 0 and 6,838,829 at december 31, 2021 and 2020, respectively; liquidation preference – 0 and 21,709 at december 31, 2021 and 2020, respectively | |||||||||||||||||
| stockholders’ equity | |||||||||||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 and 0 at december 31, 2021 and 2020, respectively; no shares issued and outstanding at december 31, 2021 and 2020 | |||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 379,824,000 | 391,084,000 | 396,823,000 | ||||||||||||||
| convertible preferred stock, 0.001 par value; authorized shares – 0 and 6,838,829 at september 30, 2021 and december 31, 2020, respectively; issued and outstanding shares – 0 and 6,838,829 at september 30, 2021 and december 31, 2020, respectively; liquidation preference – 0 and 21,709 at september 30, 2021 and december 31, 2020, respectively | |||||||||||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 and 0 at september 30, 2021 and december 31, 2020, respectively; no shares issued and outstanding at september 30, 2021 and december 31, 2020 | |||||||||||||||||
| unvested stock liability | 1,500,000 | ||||||||||||||||
| convertible preferred stock, 0.001 par value; authorized shares – 0 and 6,838,829 at june 30, 2021 and december 31, 2020, respectively; issued and outstanding shares – 0 and 6,838,829 at june 30, 2021 and december 31, 2020, respectively; liquidation preference – 0 and 21,709 at june 30, 2021 and december 31, 2020, respectively | |||||||||||||||||
| preferred stock, 0.001 par value; authorized shares – 10,000,000 and 0 at june 30, 2021 and december 31, 2020, respectively; no shares issued and outstanding at june 30, 2021 and december 31, 2020 |
We provide you with 20 years of balance sheets for Janux Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Janux Therapeutics. Explore the full financial landscape of Janux Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Janux Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.